Streetbeat News

Price Targets

DCPH

HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) and raises the price target from $25 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:36 am

SIEN

Craig-Hallum analyst Alexander Nowak has downgraded Sientra (NASDAQ:SIEN) from Buy to Hold and set a price target of $2.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:36 am

RVPH

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Reviva Pharmaceuticals and raises the price target from $10 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:33 am

PLX

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Protalix BioTherapeutics (AMEX:PLX) and raises the price target from $7 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:31 am

AMPX

HC Wainwright & Co. analyst Amit Dayal has initiated coverage on Amprius Technologies (NYSE:AMPX) with a Buy rating and a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:30 am

BTAI

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI) and maintained an $11 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:28 am

USAS

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on Americas Gold And Silver (AMEX:USAS), but has lowered the price target from $2 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:26 am

LSCC

Needham analyst Quinn Bolton maintains a Buy rating on Lattice Semiconductor (NASDAQ:LSCC) but lowers the price target from $90 to $75.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:20 am

MUX

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on McEwen Mining (NYSE:MUX) and raises the price target from $19 to $20.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:20 am

RVTY

Keybanc analyst Paul Knight has maintained an Overweight rating on Revvity (NYSE:RVTY) but lowered the price target from $170 to $110.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:17 am